MCS
    MedCannaSource

    UK vs Germany — Medical Cannabis Regulations Compared

    MedCannaSource Regulatory Team|Last updated: April 2026| 14 min read

    Introduction

    The UK and Germany are the two largest medical cannabis markets in Europe, but their regulatory frameworks differ significantly. Germany's Cannabis Act (CanG) reforms in 2024 fundamentally changed its approach, while the UK's framework remains rooted in controlled drug scheduling from 2018. This guide compares the two systems side by side for operators considering market entry, cross-border supply or dual-jurisdiction operations.

    Regulatory Bodies

    UK: MHRA (pharmaceutical regulation), Home Office DFLU (controlled drug licensing), GPhC (pharmacy regulation), CQC (clinic regulation).

    Germany: BfArM (pharmaceutical regulation and licensing under MedCanG), state-level health authorities (pharmacy and clinic oversight).

    Practical Impact

    Germany's system is primarily managed by a single federal authority (BfArM) for medical cannabis, while the UK splits responsibility across multiple bodies — adding complexity to every licence application.

    Browse Verified UK Operators

    Find licence-verified importers, manufacturers and distributors in the MedCannaSource directory.

    Browse Directory

    Prescribing Framework

    UK: CBPMs can only be prescribed by doctors on the GMC Specialist Register. GPs cannot prescribe without exceptional funding approval from their Integrated Care Board. Most prescriptions are private.

    Germany: Any doctor can prescribe medical cannabis since the MedCanG removed the narcotic prescription requirement. However, a 2025 amendment now mandates in-person consultations for initial prescriptions, with annual in-person reviews for follow-ups. This was a response to rapid growth in telemedicine prescribing platforms.

    The German system is significantly more accessible for patients, which is why patient numbers have grown much faster.

    Insurance and Reimbursement

    UK: No meaningful NHS coverage. Only three patients are known to have received NHS-funded cannabis prescriptions. Patients pay privately, typically £150–400 per month.

    Germany: Medical cannabis has been covered by statutory health insurance (GKV) since 2017. Insurers can reject applications but must provide clinical justification.

    Market Impact

    Insurance coverage is arguably the single biggest difference between the two markets and explains Germany's much larger patient population.

    Import Requirements

    UK: HO CD Import Licence per shipment + WDA(H) or MIA + 28-day MHRA notification. Typical processing: 4–8 weeks.

    Germany: BfArM Einfuhrerlaubnis (import permit). Processing times have improved to 6–8 weeks for established corridors. The EU tender process for domestic cultivation contracts has been removed under MedCanG, and companies can now market and distribute their own harvest.

    Germany's import volumes surged 400% from 19 to 80 tonnes in H1 2025.

    Download the GMP Self-Inspection Checklist

    72-item checklist aligned with MHRA expectations — free to download from the Compliance Toolkit.

    Go to Toolkit

    Manufacturing and GMP

    Both markets require EU GMP compliance. UK manufacturers need an MIA or Specials Licence from the MHRA. German manufacturers need a Herstellungserlaubnis from BfArM. The practical standards are essentially identical since both follow PIC/S GMP guidelines.

    The key difference is that Germany now allows domestic cultivators to self-distribute, while UK cultivation remains extremely restricted with very few Home Office licences granted.

    Market Size and Growth

    UK: Estimated 340,000 patients, almost entirely private prescriptions. Market growing but constrained by lack of NHS coverage and complex import procedures.

    Germany: Over 500,000 patients and growing rapidly. Insurance coverage drives accessibility. Medical cannabis imports reached 80 tonnes in H1 2025 alone. Germany is now the largest medical cannabis import market in Europe.

    Advertising and Promotion

    UK: Strict prohibition on promotion of unlicensed medicines under HMR 2012. No public advertising of CBPMs permitted.

    Germany: Heilmittelwerbegesetz (HWG) prohibits lay advertising of prescription medicines. Similar restrictions but enforcement approach differs. Both markets prohibit direct-to-consumer advertising of medical cannabis.

    Browse Verified UK Operators

    Find licence-verified importers, manufacturers and distributors in the MedCannaSource directory.

    Browse Directory

    Key Differences Summary

    AspectUKGermany
    Legal classificationClass B controlled drug (Schedule 2)Pharmaceutical product (MedCanG)
    Primary regulatorMHRA + Home OfficeBfArM
    Who can prescribeSpecialist doctors onlyAny doctor
    Insurance coverageAlmost none (private)GKV statutory coverage
    Import licence typePer-shipment HO + WDA/MIABfArM Einfuhrerlaubnis
    Import processing4–8 weeks6–8 weeks
    GMP standardEU GMP / PIC/SEU GMP / PIC/S
    Domestic cultivationExtremely restrictedExpanding rapidly
    Patient population~340,000500,000+
    Market trajectoryGrowing (constrained)Growing rapidly

    Implications for Cross-Border Operators

    Operators considering both markets should note that MHRA and BfArM GMP inspections are mutually recognised to a degree, but each market requires its own import and distribution licences. A WDA(H) in the UK does not authorise distribution in Germany, and vice versa.

    The most efficient approach for dual-market entry is to establish manufacturing or distribution in one jurisdiction and apply for import authorisation in the other. The Portugal–Germany and Canada–UK corridors are the most established supply routes.

    Compare tracked jurisdictions side by side

    Download the Regulatory Comparison Matrix from the MedCannaSource Compliance Toolkit.

    Go to Toolkit

    Get the Weekly Compliance Digest

    Every Monday, regulatory changes, licence grants, and market intelligence across tracked jurisdictions.